Fundamental IO concepts: From neoadjuvant therapy to spatial biology, novel immunomodulators, multiomics and the role of AI
df
The European Society for Medical Oncology (ESMO), in collaboration with the Society for Immunotherapy of Cancer (SITC), is excited to announce a primer program at the 2025 ESMO Immuno-Oncology Congress. The joint primer will cover a wide range of topics across the field of IO, including the current state of neoadjuvent immunotherapy of solid tumors, intratumoral immunotherapies, recombinant cytokines, immunocytokines, bispecific antibodies, AI and machine learning, spatial biology, and multiomic approaches for biomarker development.
sadf
Organizers:
Ahmad A. Tarhini, MD, PhD – H. Lee Moffitt Cancer Center & Research Institute
Daniela Thommen, MD, PhD – The Netherlands Cancer Institute
sdfasdf
Program Overview:
- Neoadjuvant immunotherapy of locoregionally advanced solid tumors
- Ahmad A. Tarhini, MD, PhD – H. Lee Moffitt Cancer Center & Research Institute
- Intratumoral immunotherapies: Fundamental aspects and potential in transforming the non-T cell-inflamed tumor microenvironment
- Mads Hald Andersen, DMSc, PhD – University of Copenhagen
- Recombinant cytokines, immunocytokines and bispecific antibodies
- Alexander Eggermont, MD, PhD – UMC Utrecht & Prinses Maxima Center
- Introduction to AI and growing application in IO
- Sine Reker Hadrup, PhD – DTU Health Tech
- Spatial biology in IO
- Daniela Thommen, MD, PhD – The Netherlands Cancer Institute
- Multiomic approaches for biomarker development and IO target identification
- Samra Turajlic, PhD,MRCP – Francis Crick Institute
DF